Centre for Addiction and Mental Health

Summary

Centre for Addiction and Mental Health is a medical facility located in TORONTO, Ontario. This center is recognized for care of Depression, Schizophrenia, Major Depressive Disorder, Psychotic Episodes, Psychosis and other specialties. Centre for Addiction and Mental Health is involved with conducting 279 clinical trials across 231 conditions. There are 36 research doctors associated with this hospital, such as Daniel Blumberger, MD, Ariel Graff, MD, PhD, Philip Gerretsen, MD, PhD, and Bernard Le Foll, MD.

Top PIs

Clinical Trials running at Centre for Addiction and Mental Health

Schizophrenia

Depression

Bipolar Disorder

Major Depressive Disorder

Dementia

SHOX Deficiency Disorder

Psychotic Episodes

Cognitive Impairment

Mild Cognitive Impairment

Smoking Cessation

Once-Daily vs Twice-Daily Clozapine

for Schizophrenia

Plasma half-life has routinely been used to establish the dosing schedule of antipsychotics; for example, it is recommended that agents with a short plasma half-life be administered multiple times per day. However, to date, several randomized controlled trials (RCTs) have shown no differences in clinical outcomes between once- and twice-daily dosing of various antipsychotics, suggesting that once-daily dosing of antipsychotics is a viable option regardless of plasma half-life. This would apply to clozapine as well; however, there have been no studies comparing once-daily vs. twice-daily dosing regimens of clozapine in terms of efficacy and tolerability. To address this gap in the literature, the investigators shall conduct a pilot, double-blind, RCT to examine efficacy and tolerability following a switch to once-daily dosing regimen of clozapine in patients with schizophrenia receiving clozapine twice a day.

Recruiting

3 awards

Phase 4

Extended Antipsychotic Dosing

for Schizophrenia

The study wishes to examine whether "extended" antipsychotic treatment, in this case, antipsychotic treatment every other day, is as effective as daily treatment. It is also evaluating whether there may be differences in terms of side effects. Participants will be randomly assigned to either the treatment as usual group (i.e., taking antipsychotic daily) or the extended dosing group (i.e., taking antipsychotic one day on, one day off). That means, like flipping a coin, there is a 50/50 chance that participants will continue on daily dosing of your antipsychotic or have it switched to every other day dosing. This study will last for 1 year. Participants will be evaluated at the beginning and every two weeks during the first 6 months, with visits once every 4 weeks for the final 6 months. In total, participants will make 22 visits over 52 weeks to the investigator's office. The investigators hypothesize that with ED, there will be no change in symptom severity but improvement in the frequency and severity of side effects, wellbeing, and functioning.

Recruiting

3 awards

Phase 4

7 criteria

tDCS

for Schizophrenia

This study will examine changes in synaptic density with transcranial direct current stimulation (tDCS) in the brains of patients with schizophrenia. Synaptic density levels will be measured using a novel positron emission tomography (PET) radiotracer \[18F\]SDM-8, which is currently the best-in-class method to quantify synaptic density in humans. This will be a companion study to a parent study by our group examining the effects of tDCS on treatment adherence in schizophrenia (REB #103-2018).

Recruiting

1 award

N/A

5 criteria